Isotope Technologies Munich SE (ITM), Germany, a leading radiopharmaceutical biotech company and Navigo Proteins GmbH, Germany, a premier protein engineering company developing optimized scaffold protein-based affinity ligands called Affilin® molecules from its Precision Targeting toolbox, announced a research collaboration for the development of a fibroblast activation protein (FAP)-targeted radiopharmaceutical program for the treatment of solid tumors. The program is planned to be added to ITM’s growing proprietary pipeline of Targeted Radionuclide Therapies spanning multiple radioisotopes and targeting molecules for optimal therapeutic effect. FAP-Targeted Radionuclide Therapy is considered a promising new approach to treating cancer within the precision oncology field.

Under the terms of the agreement, Navigo’s proprietary protein engineering platform will be used to develop and select a FAP-targeting Affilin® molecule which will then be coupled with a therapeutic radioisotope provided by ITM. Following candidate selection, ITM will have the exclusive rights to further advance the radiolabeled FAP-specific Affilin® through clinical testing in potentially multiple cancer indications. The agreement also includes a non-exclusive license for diagnostic use in radio-imaging. Further details of the agreement have not been disclosed yet.

To read more please visit:

ITM and Navigo Proteins Announce Research Collaboration to Develop FAP-targeting Radionuclide Therapy to Address Solid Tumors

Source: ITM